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The site speciftcity of the removal of iron from diferric human transfer&, at pII 7.4, by two Ec-ketohydrox- 
ypyridine chelators, 1,2-diiethyl-3-hydroxypyrid-4-one (L,) and mimosine, has been investigated using 
urea-polyacrylamide gel electrophoresis. Chelator L, removes iron preferentially from the C-terminal site 
whereas mimosine shows a small preference for iron in the N-terminal site. The removal of iron has also 
been followed spectrophotometrically and by monitoring the loss of $9Fe from [SPFe]transferrin. Both chela- 
tors are able to remove iron completely from diferric transferrin without additional mediators or reducing 
agents. 
1 I INTRODUCTION 
Human serum transferrin belongs to a family of 
iron-binding proteins found in blood, egg-white 
and secretory fluids. The transferrins are all single- 
chain polypeptides of M, -80000 and possess 2 
iron-binding sites which reside in separate do- 
mains. Studies on the physico-chemical properties 
of the metal-binding sites in a number of transfer- 
tins have reveaIed differences in the iron-bin~ng 
constants fl], the uptake of iron from iron- 
chelator complexes f2,3J and the release of iron f4] 
Abbreviations: Tf, transferrin; Fez-Tf, diferric transfer- 
rin; Fe-Tf, N-terminal monoferric transferrin; Tf-Fe, C- 
terminal monoferric transferrin; NTA, nitrilotriacetate; 
FeNTA, iron(W) nitrilotriacetate; LICAMS, 1,5,10,N’, 
N’ ’ - tris(f-sulfa - 2.3 - dihydroxybenz~yl)tria~ad~~e~ 
MECAM, 1,3,5-iV,N’,N’ ~-t~s(2,3-dihydroxy~nzoyl)- 
aminomethylben~ene~ EDTP, ethylenediamine - N,N’ - 
te~a~methylenephosphonic acid); NTP, nitrilotri- 
~met~ylenephosphonic acid); HEDP, l-hydro~eth~~ 
1, l-diphosphonic acid 
but it is still uncertain whether these observed dif- 
ferences are of physiological significance. 
Iron mobilisation from transferrin at 
physiological pH is of great importance to those 
designing iron chelators intended for the treatment 
of iron overload and other diseases of iron im- 
balance [J]. Desferrioxamine, the chelator current- 
ly used subcutaneously for the treatment of 
transfusional iron overload, cannot mobilise 
significant amounts of iron from transferrin unless 
mediators such as citrate or NTA are present f6], 
Several new tr-ketohydroxy pyridine chelators 
(e.g., 1,2-dimethyl-3-hydroxypyrid-4-0~~ Lt) were 
shown to be orally effective in the removal of iron 
from animals [5,7]. In vitro experiments at 
physiological pH showed that these chelators 
removed iron from transferrin and ferritin. In the 
experiments with transferrin biphasis reactions 
were observed and each phase corresponded to the 
reaction of the chelator with one of the binding 
sites of transferrin f5]- Other chelators found to be 
effective in the mobilisation of iron from transfer- 
rin at physiological pH include the 2-hydroxy- 
pyridine N-oxide derivatives 153, the hexadentate 
by 
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catechol-type chelators LICAMS and MECAM [S] 
and the amino alkyl phosphonic acid-derivatives 
EDTP, NTP and HEDP [9]. 
Mimosine is a naturally occurring plant product, 
the chemical structure of which is based on an LY- 
ketohydroxy metal-chelating site on a pyridine 
ring, similar to Li, but with an amino acid side- 
chain substituent. Although its chelating proper- 
ties [lo] and effects on some proteins [l l] and 
animals (121 are well known, no correlation be- 
tween all these has been established. 
In an attempt to correlate the relationship be- 
tween the chemical structure of the 2 chelators, Li 
and mimosine, and transferrin site specificity in 
iron removal, polyacrylamide gel electrophoresis 
in 6 M urea has been used here. This method 
resolved partially iron-saturated human transferrin 
into 4 bands [13] corresponding to the iron-free 
protein, the C-terminal monoferric protein, the N- 
terminal monoferric protein and the diferric pro- 
tein in order of increasing mobility [2]. The 
removal of iron from transferrin by the 2 chelators 
has also been followed by monitoring the spectral 
changes which accompany the reactions and by 
measuring the release of 59Fe from “Fe-1abelled 
diferric protein. 
2. MATERIALS AND METHODS 
Lr was prepared as previously described [5]. 
Mimosine (,&[N-(3-hydroxypyrid4-one] cu-amino- 
propionic acid) was purchased from Sigma. 
Human serum transferrin was isolated from 
fresh plasma by immunoaffinity chromatography 
[14]. The protein, in 0.1 M NaHCOs, was made 
iron-saturated by addition of excess iron 
nitrilotriacetate. Unbound iron was removed by 
gel filtration on Sephadex G-25 equilibrated with 
50 mM N&HCOs and the protein was then freeze- 
dried. 
Diferric human transferrin (32.5 /IM) was taken 
up in 50 mM Tris-HCl, pH 7.4, and incubated at 
20°C with iron-free chelators (4 mM). The 
removal of iron from the protein was followed 
spectrophotometrically using a Pye Unicam 
SP 1800 spectrophotometer. Samples were taken 
over a period of about 4 h and applied to a 
polyacrylamide gel containing 6 M urea. 
Polyacrylamide gels were stained with PAGE blue 
83 (BDH) and after destaining were scanned at 
142 
570 nm on a Camlab EC 910 Transmission Den- 
sitometer. The relative amounts of the 4 transfer- 
rin bands were determined by cutting out and 
weighing the peaks from the densitometric traces 
and these values were then used to calculate the 
iron-saturation of each sample. 
[59Fe]Transferrin was prepared as described [5] 
by mixing [59Fe]NTA (5 ,&i) in 0.1 M Tris-HCl, 
pH 7.4, with apotransferrin (Sigma) in the same 
buffer which also contained 10 mM NaHCO3, and 
in the ratio of 1.4 pug: 1 mg apotransferrin, for 
100% iron saturation. The mobilisation of 59Fe 
from [“Feltransferrin was studid by dialysing a 
fresh solution of the labelled protein (1.5 ml) 
against 15 ml of the chelator (4 mM) in 0.1 M 
Tris-HCl, pH 7.4, in a stoppered glass tube con- 
taining a magnetic flea. The amount of 59Fe in the 
dialysate and the dialysis bag was determined using 
an LKB Wallac 1280 Ultragamma counter. 
3. RESULTS AND DISCUSSION 
Figs 1 and 2 show that under the conditions of 
the experiments both Li and mimosine are able to 
remove iron completely from diferric human 
transferrin, at pH 7.4, within 4 h. It is apparent 
a b c d I f n h i i 
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R-Tf- 
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Fig.1. Urea-polyacrylamide gel electrophoresis of 
diferric human transferrin incubated with chelator Lr 
(1,2-dimethyl-3-hydroxypyrid-4-one). (a) Partially iron- 
saturated sample of transferrin containing iron-free 
transferrin (Tf), C-terminal monoferric transferrin (Tf- 
Fe), N-terminal monoferric transferrin (Fe-Tf), and 
diferric transferrin (FezTf). (b-j) Samples taken from 
reaction mixture at (b) 0, (c) 5, (d) 10, (e) 16, (f) 20, (g) 
30, (h) 40, (i) 88, (j) 200 min. 
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Fig.2. Urea-polyacrylamide gel electrophoresis of 
diferric human transferrin incubated with mimosine. (a) 
Partially iron-saturated sample of transferrin containing 
iron-free transferrin (Tf), C-terminal monoferric 
transferrin (Tf-Fe), N-terminal monoferric transferrin 
(Fe-Tf) and diferric transferrin (FezTf). (b-j) Samples 
taken from reaction mixture at (b) 0, (c) 5, (d) 10, (e) 16, 
(f) 20, (g) 30, (h) 40, (i) 80, (j) 110 min. 
that the removal of iron is not a random process 
and the 2 chelators remove iron preferenti~ly from 
different sites on the protein. In particular L1, 
which was shown previously to react in a biphasic 
process with diferric transferrin IS], removes iron 
preferentially from the C-terminal site (fig.l), the 
thermodynamically more stable one [ 1,2]. 
Mimosine, however, shows a slight preference for 
iron in the N-terminal site (fig.2). This ability of 
mimosine to remove iron from transferrin may be 
partly associated with the toxic effects of this plant 
product El2J. 
When iron is transferred from diferric transfer- 
rin to LI there is an increase in absorbance at 
460 nm which corresponds to the formation of the 
chelator-iron complex [S]. A similar increase has 
now been observed using mimosine. This increase, 
when normalised, is a measure of the percentage 
loss of iron from the protein. The time-dependent 
changes in the iron saturation of the transferrin, as 
determined from the densitometrically scanned 
urea-polyacrylamide gels, and the formation of the 
iron-chelator complexes, as determined from the 
absorption spectra, upon incubation with LZ and 
mimosine are shown in figs 3 and 4. There is good 
agreement between the values obtained by the 2 
procedures and although the 2 chelators remove 
iron preferentially from a different site on 
TIME fmin) 
Fig.3. Time dependence of removal of iron from diferric 
human transferrin by chelator LI (1,2-dimethyl-3- 
hydroxypyrid-4-one). Results obtained from (A) change 
in absorbance at 460 nm and (0) quantitation of urea- 
polyacrylamide gels. 
transferrin the overall reaction rates seem to be 
similar. Furthermore, the results of the dialysis ex- 
periments using [‘gFe]transferrin (table 1) confirm 
that both LX and mimosine can remove iron effi- 
ciently from the iron-saturated protein without the 
assistance of a mediator or reducing agent. 
It is interesting to observe that although the 
chelating sites of L1 and mimosine are the same 
they display different preferences for iron in the 2 
sites on human transferrin. These differences may 
be related to the charge and size of the ring substi- 
tuents in the two chelators. At physiological pH 
the 2 methyl substituents cause Ll to be neutral 
whereas mimosine has a zwitterionic side chain. 
Subtle differences between the nature and arrange- 
ment of the ligands in the 2 iron-bin~ng sites of 
transferrin would then be reflected in the way the 
2 chelators remove iron from the protein. In a 
study of the iron-donating properties of NTA and 
2 of its analogues [3] differences were observed in 
the order of occupancy of the N- and C-terminal 
sites. 
The results of this study show that the 2 cy- 
ketohydroxypyridine chelators, Ll and mimosine, 
behave differently towards the 2 thermody- 
namically non-equivalent sites on transferrin 
although the overall rates of iron removal are very 
similar. From further studies on the removal of 
iron from transferrin by other analogues of these 
chelators it should be possible to correlate chelator 
structure with site specificity. This information 
143 
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Fig.4. Time dependence of removal of iron from diferric 
human transferrin by mimosine. Results obtained from 
(A) change in absorbance at 460 nm and (0) 
quantitation.of urea-polyacrylamide gels. 
Table 1 
59Fe mobilisation from [59Fe]transferrin 
Conditions of olo 59Fe mobilised 
experiment 
Mimosine Buffer 
(4 ?M) (4 mM) blank 
10 FM [59Fe]transferrin, 
4 h, 26’C 89.5 80.0 0.5 
5 pM [59Fe]transferrin, 
6 h, 26’C 88.0 89.0 1.0 
will assist in the design and development of 
chelators which can be used as probes for studying 
iron metabolism and for the treatment of iron 
imbalance. 
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